BioNTech Completes Acquisition of InstaDeep
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design and developmentInstaDeep to operate as...
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design and developmentInstaDeep to operate as...
Niagara Falls, NY, July 31, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular...
Dr. Sparks to transition from Inspire’s Board of Directors to a full-time role on the Executive Leadership TeamMINNEAPOLIS, July 31,...
SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing...
SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the successful launch of its...
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for...
CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the RegionDUBLIN, Ireland...
Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and...
Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging...
Initial data expected in first half of 2024NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)...
Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational...
PALO ALTO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180LS” or the “Company”), today...
Media Release Mini Oral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus...
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the...
Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end...
Cash balance of $18.5 million as at March 31, 2023Revenue of $3.95 million (vs 2022: $2.3 million, an increase of...
New Product Showing Encouraging Early ResultsSHERMAN OAKS, CA / ACCESSWIRE / July 31, 2023 / Avenir Wellness Solutions, Inc. (OTC:CURR)...
LUND, SE / ACCESSWIRE / July 31, 2023 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Tumorad® into clinicJANUARY - JUNE IN BRIEFNet...
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitisConfirmed seven total events of non-occlusive/occlusive...